Production of fertile XY female animals by silencing of genes on the Y chromosome

Patent metadata

Field	Value
Publication number	US-12041918-B2
Application number	US-202017119076-A
Country	US
Kind code	B2
Filing date	Dec 11, 2020
Priority date	Sep 17, 2015
Publication date	Jul 23, 2024
Grant date	Jul 23, 2024

Abstract

Methods and compositions are provided for generating F0 fertile XY female animals. The methods and compositions involve making XY pluripotent or totipotent animal cells, in vitro cell cultures, or embryos that are capable of producing a fertile female XY animal in an F0 generation. Such cells, embryos, and animals can be made by silencing a region of the Y chromosome. Optionally, the cells can also be cultured in feminizing medium such as a low-osmolality medium and/or can be modified to decrease the level and/or activity of an Sry protein. Methods and compositions are also provided for silencing a region of the Y chromosome in an XY pluripotent or totipotent animal cell, or in vitro cell cultures, embryos, or animals derived therefrom, by maintaining an XY pluripotent or totipotent animal cell in a feminizing medium. Methods and compositions are also provided for maintaining a population of XY pluripotent or totipotent animal cells in a feminizing medium and selecting cells or clones having increased capabilities for producing a fertile female XY animal in an F0 generation. Methods and compositions are also provided for screening for compounds with feminizing activity or for optimizing concentrations of components in feminizing media.

First claim

We claim:

1. A method for selecting a donor mouse XY embryonic stem (ES) cell for producing a fertile, phenotypically female XY mouse, comprising:
(a) culturing a population of mouse XY ES cells originating from the same cell line or the same clone or having the same genotype in a low-osmolality medium comprising a base medium and supplements suitable for maintaining the pluripotency of the mouse XY ES cells, wherein the base medium comprises sodium bicarbonate in a concentration of about 18 mM to about 26 mM, and wherein the low-osmolality medium has an osmolality of from about 216 mOsm/kg to about 322 mOsm/kg;
(b) assaying at least two of the mouse XY ES cells in the population of mouse XY ES cells for mRNA expression of Ddx3y, Uty, and Eif2s3y; and
(c) selecting the mouse XY ES cell having the lowest mRNA expression of Ddx3y, Uty, and Eif2s3y relative to the other assayed cells as a donor mouse XY ES cell for producing a fertile, phenotypically female XY mouse in an F0 generation,
wherein the donor mouse XY ES cell has at least 90% decreased mRNA expression of Ddx3y, Uty, and Eif2s3y as compared to a control mouse XY ES cell cultured in a non-feminizing medium or that lacks the capability or has reduced capability to produce XY female mice notwithstanding its being cultured in the low osmolality medium.

2. The method of claim 1 , wherein the donor mouse XY ES cell lacks mRNA expression of Ddx3y, Uty, and Eif2s3y.

3. The method of claim 1 , wherein the mouse XY ES cells are cultured in the low-osmolality medium for at least 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 2 weeks, 3 weeks, or 4 weeks prior to assaying step (b).

4. The method of claim 1 , wherein the donor mouse XY ES cell is a VGF1 mouse ES cell.

5. The method of claim 1 , wherein the low-osmolality medium has one or more of the following properties:
(I) the low-osmolality medium has an osmolality of from about 218 mOsm/kg to about 322 mOsm/kg;
(II) the low-osmolality medium has an osmolality of 218 mOsm/kg;
(III) the low-osmolality medium has a conductivity of about 11 mS/cm to about 13 mS/cm;
(IV) the base medium comprises a salt of an alkaline metal and a halide in a concentration of about 50 mM to about 110 mM;
(V) the base medium comprises sodium chloride in a concentration of about 50 mM to about 110 mM; and
(VI) the base medium comprises sodium chloride in a concentration of 87±5 mM, and the low-osmolality medium has an osmolality of 261±26 mOsm/kg.

6. The method of claim 1 , wherein the base medium comprises sodium chloride in a concentration of about 3 mg/mL and sodium bicarbonate in a concentration of about 2.2 mg/mL, and the low-osmolality medium has an osmolality of about 216 mOsm/kg.

7. The method of claim 1 , wherein the donor mouse XY ES cell is from a C57BL/6 strain.

8. The method of claim 1 , wherein the Y chromosome in the donor mouse XY ES cell is from a C57BL/6 strain, a 129 strain, or a BALB/c strain.

9. The method of claim 1 , wherein the donor mouse XY ES cell is from a mix of a C57BL/6 strain and a 129 strain.

10. The method of claim 1 , wherein the donor mouse XY ES cell comprises a targeted genetic modification in a target genomic locus.

11. The method of claim 10 , wherein the targeted genetic modification comprises an insertion, a deletion, a knockout, a knockin, a point mutation, or a combination thereof.

12. The method of claim 1 , further comprising:
(d) introducing the donor mouse XY ES cell into a mouse host embryo;
(e) introducing the mouse host embryo from step (d) into a recipient female mouse and gestating the mouse host embryo; and
(f) obtaining F0 XY mouse progeny comprising a phenotypically female XY mouse, wherein upon attaining sexual maturity the F0 phenotypically female XY mouse is fertile and fecund.

13. The method of claim 12 , further comprising:
(g) breeding the F0 XY fertile female mouse to produce progeny.

14. The method of claim 13 , wherein at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or all of the XY progeny produced in step (g) are phenotypically male and fertile.

15. The method of claim 13 , wherein none of the XY progeny produced in step (g) are phenotypically female.

16. The method of claim 13 , wherein the breeding comprises crossing the F0 XY fertile female mouse with a cohort F0 XY male mouse, wherein the F0 XY fertile female mouse and the F0 XY male mouse each is heterozygous for a genetic modification, and obtaining an F1 progeny mouse that is homozygous for the genetic modification.

17. The method of claim 12 , wherein the host embryo is a pre-morula stage embryo, and step (d) further comprises culturing the host embryo to the blastocyst stage.

18. The method of claim 12 , wherein the donor mouse XY ES cell is cultured in the low-osmolality medium for at least 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 2 weeks, 3 weeks, or 4 weeks prior to introduction into the host embryo.

Assignees

• Regeneron Pharma

Inventors

• Schmahl Jennifer
• Frendewey David
• Kuno Junko
• Siao Chia-Jen
• Droguett Gustavo
• Bai Yu
• Auerbach Wojtek

Classifications

• G01N33/5073

  Stem cells · CPC title

• C12Q2600/158

  Expression markers · CPC title

• C12Q2600/156

  Polymorphic or mutational markers · CPC title

• C12Q2600/136

  Screening for pharmacological compounds · CPC title

• C12Q1/6876 Primary

  Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes · CPC title